Evidence map›Paper›PMID 41309883›Full record

ArticleScientific reports2025

Wearable inertial device for monitoring Parkinson's disease symptoms: a pilot study in a controlled environment.

Margaux Poleur, Teresa Gidaro, Stéphanie Delstanche, Jean-Marc Gurruchaga, Alexis Tricot, Léopold Bancel, Stéphane Palfi, Laurent Servais, Bertrand Degos

Abstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Margaux Poleur *University Department of Neurology, Citadelle Hospital, Liège, Belgium. margaux.poleur@citadelle.be.
Teresa Gidaro *Institute of Myology, GH La Pitié-Salpêtrière, Paris, France.
Stéphanie DelstancheUniversity Department of Neurology, Citadelle Hospital, Liège, Belgium.
Jean-Marc GurruchagaGroupe de recherche clinique translationnelle OPTIMA, Institut Mondor de Recherche Biomédical, Henri Mondor Academic Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Est Créteil, INSERM Laboratory U955 of Translational NeuroPsychiatry, Institut Mondor de Recherche Biomédicale, Créteil, France.
Alexis TricotSYSNAV, Vernon, France.
Léopold BancelSYSNAV, Vernon, France.
Stéphane PalfiGroupe de recherche clinique translationnelle OPTIMA, Institut Mondor de Recherche Biomédical, Henri Mondor Academic Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Est Créteil, INSERM Laboratory U955 of Translational NeuroPsychiatry, Institut Mondor de Recherche Biomédicale, Créteil, France.
Laurent Servais *University Department of Neurology, Citadelle Hospital, Liège, Belgium.
Bertrand Degos *Neurology Department, Réseau NS-PARK/FCRIN, Avicenne Hospital, APHP, Universitaires de Paris-Seine Saint Denis (HUPSSD), Sorbonne Paris Nord, Bobigny, Hôpitaux, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical assessments for Parkinson's disease depend on clinician-administered scales, which have limitations in sensitivity and real-world applicability. Wearable inertial sensors offer a promising approach for objective and continuous monitoring of PD motor symptoms. This study aimed to evaluate the feasibility and accuracy of a magneto-inertial wearable device in detecting key PD motor manifestations-tremor, akinesia, and dyskinesia-on an individual movement basis. Ten PD patients undergoing pre-surgical evaluation for deep brain stimulation were included in a pilot multicentric study. Participants performed a Levodopa challenge test while wearing an inertial measurement unit on the most affected wrist and ankle. MDS-UPDRS Part III and video recordings were obtained to compare sensor performance to expert evaluations. Algorithms analyzed acceleration and angular velocity data to detect tremor, akinesia and dyskinesia. The sensor demonstrated high sensitivity (100%) and specificity (≥ 93%) for tremor and akinesia detection, with an overall accuracy exceeding 94%. Performance metrics were less promising for dyskinesia detection. Levodopa significantly reduced tremor (p = 0.0247) and increased dyskinesia (p = 0.0169), confirming sensor responsiveness to pharmacological effects. Magneto-inertial wearable device showed promising accuracy for the objective assessment of PD motor symptoms in a controlled environment. These findings support further validation in real-life conditions.

Indexed as

Parkinson DiseaseWearable Electronic DevicesAccelerometryAgedAntiparkinson AgentsDyskinesiasFemaleHumansLevodopaMaleMiddle AgedPilot ProjectsTremorAntiparkinson AgentsLevodopaAkinesiaLevodopa-induced dyskinesiaParkinson’s diseaseTremorWireless sensor

Identifiers

PMID41309883
PMCPMC12748983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.